TECHWIRE 30
(CIX: WRAL30)  1,100.23  up arrow+1.71  (0.16 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NQ: Apple)  96.86  down arrow-0.33  (-0.34 %)  Updated: 01:27 PM EDT, Jul 24 2014
(NY: QUINTILES)  54.81  down arrow-0.19  (-0.35 %)  Updated: 01:25 PM EDT, Jul 24 2014
(OP: BASF SE)  110.61  down arrow-1.98  (-1.76 %)  Updated: 01:19 PM EDT, Jul 24 2014
(NQ: BioCryst)  12.17  up arrow+0.05  (0.41 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NQ: BioDelivery)  12.46  down arrow-0.03  (-0.2 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NQ: CEMP)  9.40  down arrow-0.17  (-1.78 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NQ: Cisco Systems)  25.84  up arrow+0.16  (0.62 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NQ: Cree)  48.56  down arrow-0.39  (-0.79 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NQ: DARA)  1.45  down arrow-0.04  (-2.68 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NY: EMC CORPORATION)  28.89  up arrow+0.14  (0.49 %)  Updated: 01:27 PM EDT, Jul 24 2014
(NQ: Extreme Networks)  4.93  down arrow-0.02  (-0.3 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NQ: FB)  75.91  up arrow+4.62  (6.48 %)  Updated: 01:27 PM EDT, Jul 24 2014
(NY: GLAXOSMITHKLINE)  50.00  down arrow-0.05  (-0.09 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NQ: GOOG)  594.35  down arrow-1.63  (-0.27 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NY: IBM)  194.95  up arrow+1.32  (0.68 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NY: LH)  106.23  up arrow+0.6  (0.57 %)  Updated: 01:26 PM EDT, Jul 24 2014
(OP: Lenovo Group)  27.89  up arrow+0.84  (3.11 %)  Updated: 01:23 PM EDT, Jul 24 2014
(NY: MRK)  58.16  up arrow+0.05  (0.08 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NQ: Microsoft Corp)  44.45  down arrow-0.42  (-0.94 %)  Updated: 01:27 PM EDT, Jul 24 2014
(NQ: NTAP)  38.13  up arrow+0.2  (0.53 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NY: NOVARTIS AG)  89.16  up arrow+0.14  (0.16 %)  Updated: 01:25 PM EDT, Jul 24 2014
(OP: Novozymes A/S)  50.61  down arrow-0.02  (-0.04 %)  Updated: 01:24 PM EDT, Jul 24 2014
(NY: PFIZER)  30.39    (0 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NQ: Pozen)  7.95  down arrow-0.1  (-1.24 %)  Updated: 01:22 PM EDT, Jul 24 2014
(NY: RED HAT)  56.17  up arrow+0.29  (0.52 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NQ: BBRY)  10.26  up arrow+0.43  (4.42 %)  Updated: 01:27 PM EDT, Jul 24 2014
(NQ: Salix)  131.61  down arrow-0.74  (-0.56 %)  Updated: 01:26 PM EDT, Jul 24 2014
(NQ: SQI)  15.25  up arrow+0.22  (1.46 %)  Updated: 01:24 PM EDT, Jul 24 2014

Posts tagged “Chimerix ”

Updated July 16

Josh Hardy, treated with experimental Chimerix drug, is going home

Chimerix, the Durham-based drug company working on experimental medicine that could save the life of a seven-year-old Josh Hardy, was granted approval by the U.S. Food and Drug Administration to administer the drug to the boy in March. On Wednesday, his mother said he is doing well and going home.

Josh Hardy Josh Hardy

May 2

Premium Lock Durham firm's good FDA news; Chimerix eyes $200M; SEAL Innovation expands; Snapchat adds chat; eBay settles antitrust case

Bulldog In today's Bulldog blog roundup of technology and life science news, get the latest about drug firm Parion Sciences, a $200 million stock offering from Chimerix, details about Raleigh-based startup SEAL Innovation's expansion, Snapchat finally adds chat, and eBay settles an antitrust case.

April 9

Premium Lock Chimerix names new CEO after Moch steps down

Chimerix Kenneth Moch has resigned as chief executive of the biopharmaceutical company to "pursue other interests," the company announced on Wednesday while also naming his replacement.

Updated March 19

Premium Lock Window of opportunity: More life science IPOs in Triangle is good for all

Life Sciences A spate of Triangle life science IPOs raised more total money than those in Boston and New York in 2013, and more followed early this year. Has this open IPO window affected biotech and life science fundraising in the Triangle? Will the window remain open? One area VC suggests we may look back on 2010-2015 as a watershed time for the regional industry.

March 12

Premium Lock Experimental Chimerix drug request granted for sick boy

Chimerix, the Durham-based drug company working on experimental medicine that could save the life of a seven-year-old Virginia child, was granted approval by the U.S. Food and Drug Administration to administer the drug to the boy, the company said Tuesday evening.

Josh Hardy Josh Hardy

Updated February 28

Premium Lock IPO Watch: Scynexis joins Square 1 in pipeline of Triangle firms going public

Wall Street Quintiles led the class of Triangle IPOs in the last year at nearly $1 billion in value, but ChannelAdvisor's stock is showing remarkable strength. So is Aerie Pharmaceuticals. With Scynexis filing to go public Thursday, WRALTechWire updates what has happened on the stock "exit route" for regional firms and how their stocks have fared since.

Updated October 25, 2013

Premium Lock Aerie Pharma cuts stock price, adds shares for $67M IPO; Chimerix sells more stock

Aerie Pharmaceuticals Aerie Pharmaceuticals' $67 million IPO was priced at $10 per share, well below the $12 to $14 per share range the company had previously set. Read more about the offering.

October 8, 2013

Premium Lock 'Certain' Chimerix stockholders plan to sell shares

Chimerix Chimerix, a Durham-based drug developer that went public in April for more than $100 million, says in an SEC filing that "certain stockholders" are looking to sell their shares.

May 13, 2013

Premium Lock Durham drug firm Chimerix reports $9.1M quarterly loss

Chimerix The company, which went public in April, reports a drop in revenue and an increase in expenses. But stock rallies 4 percent on the news.

Updated December 10, 2012

Premium Lock Chemistry among people, companies is crucial to biochemistry deals

Finding the right chemistry is crucial to biotech deals, as two major life science partnerships in the Triangle have shown this year: GSK and Liquidia; Merck and Chimerix.

Drug deal Drug deal

November 12, 2012

Premium Lock RTP drug firm Chimerix names former GSK exec as chief medical officer

Chimerix Dr. Michelle Berrey, MD, joins the firm from Pharmasset where she also served as CMO. Pharmasset was acquired by Gilead Sciences earlier this year.

July 25, 2012

Premium Lock Merck licenses HIV compound from RTP-based Chimerix

Fighting HIV In exchange for exclusive worldwide license and funding the drug development and commercialization costs, Merck will pay Chimerix $17.5 million on top of royalties on future sales and milestone payments of up to $151 million.

February 7, 2012

Premium Lock Startup Chimerix reports positive test news for transplant drug

Chimerix The company is studying the compound for the prevention of cytomegalovirus diseases, or CMV, in patients who have had stem cell transplants.

June 28, 2011

Premium Lock Durham biotech firm wins round in $2B contract battle

Biohazard symbol Chimerix fought the award of a sole-source contract for a potential smallpox treatment to another firm and convinces the government agency involved to overturn it. Now, Chimerix can compete for a lucrative deal, CEO says.

February 17, 2011

Premium Lock Chimerix lands $24.8 million contract for smallpox drug

Chimerix Under the terms of this BARDA contract, Chimerix potentially could net almost $81.1 million total.

February 14, 2011

Premium Lock Chimerix secures $45M round for antiviral medicines

Chimerix New funding is aimed at further development of vitally important new antiviral medicines for the treatment of life-threatening diseases.

May 7, 2010

Premium Lock Chimerix expands leadership with business development post

Chimerix The biotechnology firm recently reshuffled its management team, board.

May 4, 2010

Premium Lock RTP biotech firm Chimerix names new CEO, shuffles board

Chimerix The company, which is developing antiviral treatments that can be taken orally, promotes its chief operating officer to top post. Its former CEO is now chief science officer.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll